Universität Wien

301907 VO Development of novel cancer immunotherapies (2023W)

from target identification through target validation to clinical trials

3.00 ECTS (2.00 SWS), SPL 30 - Biologie
ON-SITE
Moodle

Registration/Deregistration

Note: The time of your registration within the registration period has no effect on the allocation of places (no first come, first served).
Register/Deregister for this course

Details

Language: English

Examination dates

Lecturers

Classes (iCal) - next class is marked with N

The lecture will be held in english and hybrid

  • Monday 02.10. 15:00 - 17:00 BZB/Seminarraum 3, 6.Ebene 6.105, Dr.-Bohrgasse 9, 1030 Wien
  • Monday 09.10. 15:00 - 17:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
  • Monday 16.10. 15:00 - 17:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
  • Monday 23.10. 13:00 - 15:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
  • Monday 06.11. 15:00 - 17:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
  • Tuesday 07.11. 09:00 - 11:00 BZB/Seminarraum 3, 6.Ebene 6.105, Dr.-Bohrgasse 9, 1030 Wien
  • Monday 13.11. 10:00 - 12:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien
  • Monday 20.11. 09:00 - 18:00 BZB/Seminarraum 3, 6.Ebene 6.105, Dr.-Bohrgasse 9, 1030 Wien

Information

Aims, contents and method of the course

Currently, promising results are being achieved in the field of cancer immunotherapy. However, not every patients is responding to the available therapies. The lecture will:
(1) give an overview on current therapies: their potential, their risks and where they currently fail: description of different therapy modalities: Antibodies (check point inhibitors, protacs, T cell engagers , neutralizing Antibodies) and small molecule therapies (inhibitors and agonists)
(2) description on how cancer imrnunotherapy targets are being discovered: available methods for target screening and how to validate them
(3) description how to validate the targets
(4) explain why biomarker research is important for the success oftherapies
(5) describe the different stages of clinical trials

Assessment and permitted materials

written exam

Minimum requirements and assessment criteria

100-87%: Sehr Gut ( I ); 87,99-75%: Gut (2); 74,99-62%: Befriedigend (3); 6 I ,99-50%: Genügend (4); < 50%: Nicht Genügend (5)

Examination topics

The lecture concludes with a written exam
the exam consists of 5 multiple choice and 5 open questions

Reading list

I will talk about the newest developments of the emerging fields of cancer immunotherapy.
In the lecture i will provide the studens with references of the discussed topics and research articles

Association in the course directory

MMB IV-2,MMB W-2, MMB IV., MMEI II-3.2,MMEI III, WZB, MNEU V.

Last modified: Tu 24.10.2023 08:28